INDEX

Abilify, 163
Abrams, David, 270
Abscesses, 53
Abstinence syndrome, 93
Abstinence violation effect (AVE), xvii, 19, 279, 291–292
Abuse, 4–7, 9, 10
Acceptance, spirituality and, 217–219
Acetylcholine, 137, 138
Acid. See Lysergic acid diethylamide (LSD)
Acne, steroids and, 41
Action paradigm, 254, 270
Action stage, 257–258
RPT and, 296
Activities of daily living (ADL), 164
Acupuncture, 75, 81
Acute Stress Disorder, 176
Adam. See Methyleneoxymethamphetamine (MDMA)
Adderall, 187
Addict, xvii, xviii
Addiction:
  biological basis of chemical, 34
  culture of, xvi, 203–204
  models of, 274–275
Addiction Professional, 235
Addictive behavior model, 274, 275
Administration, route of, 129
Adolescent treatment, 75
Adoption studies, 135–136
Aerosols, 42. See also Inhalants
Affective flattening, 161–162
Against medical advice (AMA), 84
Aggressiveness, steroids and, 41
Agitation, alcohol abstinence syndrome and, 98, 99
Agonists, 110–112
Alanine transferase (ALT), 124
Al-Anon, 246
Alcohol:
  addiction medications and, 132–134
  assessing withdrawal potential, 98
  tools for, 98–99
  medical consequences of, 122
  substance classifications and, 32
  withdrawal syndrome
    level of care, 101–102
    pharmacologic treatment of, 102–103
    sedative-hypnotic treatment, 103–105
  symptoms, 99–100
Alcoholics Anonymous (AA), xvii, xviii
  founding of, 22, 79–80
  motivation and, 18
  spirituality and, 213–214
  stages of change, 260–261
Alcohol-induced liver disease (ALD), 123–124
Alcohol Use Disorders Identification Test (AUDIT), 51, 55, 99
Alcohol Use Inventory (AUI), 51
Alogia, 162
Amantadine, addiction medications and, 132
Ambivalence, 19, 20–21, 276
contemplation and, 256–257
resolving, 265–267
American Psychiatric Association (APA), 86
American Society of Addiction Medicine (ASAM), xiv, 55–56, 71, 86, 94, 149
Amphetamine, 27, 35. See also Stimulants
Amyl nitrate, 42–43
Amytal, 32
Anabolic steroids, 41–42
Anadrol, 41. See also Anabolic steroids
Anesthesia, depressants and, 33
Angel dust, 40. See also Phencyclidine (PCP)
Anger management, 75
Anorexia, alcohol abstinence syndrome and, 98
Antabuse, 132–133
Antagonists, 110–112
Antidepressants, anxiety disorders and, 177
Anti-Opioid Bill, 27
Antisocial Personality Disorder, 181
Anxiety Disorders, xv, 139, 152
Avoidant Personality Disorder and, 185
Avolition, 162
Ativan:
anxiety disorders and, 177
medical consequences of, 128
substance classifications and, 32
Attention-Deficit/Hyperactivity Disorder (ADHD), 35, 36, 132, 152, 186–188
Atypical antidepressants, 168
Auditory hallucinations, 159, 160
Authentic power, 214
Autobiography, RPT and, 284
Aventyl, 168
Aversion therapy, 277
Avoidant Personality Disorder, 184–185
Avolition, 162
Baclofen, 132
Balancing, 221
Baldness, steroids and, 41
Barbiturates, 27
medical consequences of, 128
substance classifications and, 32
withdrawal and, 105
Bean. See Methyleneoxymethamphetamine (MDMA)
Behavioral change, counseling skills and, 251–254
available resources, 267–269
coping skills, 269–271
preventing relapse, 271
resolving ambivalence, 265–267
stages-of-change strategies, 264–265
understanding the stages of, 254–264
BenGay, 31
Bennies. See Amphetamine
Benzodiazepines:
medical consequences of, 128
substance classifications and, 32
treating anxiety disorders and, 177
withdrawal and, 105
Betty Ford Clinic, 202–203, 234–235
Bibliotherapy, 167
Bicultural addict, 203–204
Binge drinking, 73
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biomedical conditions, SUDs and</td>
<td>119–120</td>
</tr>
<tr>
<td>blood-borne diseases</td>
<td>124</td>
</tr>
<tr>
<td>cardiovascular diseases</td>
<td>121–123</td>
</tr>
<tr>
<td>chronic pain</td>
<td>130–131</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>126–127</td>
</tr>
<tr>
<td>liver disease</td>
<td>123–126</td>
</tr>
<tr>
<td>pulmonary and respiratory diseases</td>
<td>128–129</td>
</tr>
<tr>
<td>renal damage</td>
<td>130</td>
</tr>
<tr>
<td>tuberculosis</td>
<td>129–130</td>
</tr>
<tr>
<td>viral hepatitis</td>
<td>124–126</td>
</tr>
<tr>
<td>Biopsychosocial assessment</td>
<td>48</td>
</tr>
<tr>
<td>Biopsychosocial influences</td>
<td>10–13</td>
</tr>
<tr>
<td>Biphetamine</td>
<td>35</td>
</tr>
<tr>
<td>Bipolar Disorder</td>
<td>169–172</td>
</tr>
<tr>
<td>Bizarre delusions</td>
<td>159</td>
</tr>
<tr>
<td>Black beauties.</td>
<td></td>
</tr>
<tr>
<td>Blood-alcohol concentration (BAC)</td>
<td>100</td>
</tr>
<tr>
<td>Blood pressure, alcohol abstinence syndrome</td>
<td>98</td>
</tr>
<tr>
<td>Blotter.</td>
<td></td>
</tr>
<tr>
<td>Bodybuilding.</td>
<td></td>
</tr>
<tr>
<td>Borderline features</td>
<td>153</td>
</tr>
<tr>
<td>Borderline Personality Disorder</td>
<td>181–183</td>
</tr>
<tr>
<td>Bradley, Nelson</td>
<td>80, 85</td>
</tr>
<tr>
<td>Breast development, steroids and</td>
<td>41</td>
</tr>
<tr>
<td>Breathalyzer readings</td>
<td>xv, 100</td>
</tr>
<tr>
<td>Bup, 111</td>
<td></td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>77</td>
</tr>
<tr>
<td>addiction medications and</td>
<td>131</td>
</tr>
<tr>
<td>agonists and antagonists</td>
<td>110</td>
</tr>
<tr>
<td>Bupropion</td>
<td>134, 168</td>
</tr>
<tr>
<td>Buspirone</td>
<td>134</td>
</tr>
<tr>
<td>Butyl nitrate</td>
<td>42</td>
</tr>
<tr>
<td>Caffeine, 35–36.</td>
<td></td>
</tr>
<tr>
<td>See also Stimulants</td>
<td></td>
</tr>
<tr>
<td>Campral</td>
<td>134</td>
</tr>
<tr>
<td>Cancer</td>
<td>130</td>
</tr>
<tr>
<td>Cannabinoids, 39–40.</td>
<td></td>
</tr>
<tr>
<td>See also Marijuana</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>171</td>
</tr>
<tr>
<td>Cardiovascular diseases, xv</td>
<td>xvi</td>
</tr>
<tr>
<td>Cat valiums, 41.</td>
<td></td>
</tr>
<tr>
<td>See also Ketamine</td>
<td></td>
</tr>
<tr>
<td>Catapres, 108</td>
<td></td>
</tr>
<tr>
<td>Catatonic behavior</td>
<td>159, 160, 162</td>
</tr>
<tr>
<td>The Celestine Prophecy</td>
<td>224</td>
</tr>
<tr>
<td>Center for Applied Sciences (CENAPS)</td>
<td>294, 296</td>
</tr>
<tr>
<td>Center for Substance Abuse Treatment (CSAT)</td>
<td>16</td>
</tr>
<tr>
<td>Central nervous system (CNS), psychoactive substances and</td>
<td>4</td>
</tr>
<tr>
<td>Chemically abusing mentally ill (CAMI)</td>
<td>150–151</td>
</tr>
<tr>
<td>Child neglect</td>
<td>53</td>
</tr>
<tr>
<td>Childhood roles</td>
<td>195–196</td>
</tr>
<tr>
<td>Chloroform, 42.</td>
<td></td>
</tr>
<tr>
<td>See also Inhalants</td>
<td></td>
</tr>
<tr>
<td>Choking, inhalants</td>
<td>43</td>
</tr>
<tr>
<td>Cibalith-S</td>
<td>171</td>
</tr>
<tr>
<td>Circumstantiality</td>
<td>158, 159</td>
</tr>
<tr>
<td>Clean time</td>
<td>260–261</td>
</tr>
<tr>
<td>Clinical Guide to Alcohol Treatment: The Community Reinforcement Approach</td>
<td></td>
</tr>
<tr>
<td>Clinical Institute Withdrawal Assessment of Alcohol, revised (CIWA-Ar)</td>
<td>98–99, 100</td>
</tr>
<tr>
<td>Clonidine</td>
<td>131</td>
</tr>
<tr>
<td>opioid withdrawal and</td>
<td>108</td>
</tr>
<tr>
<td>Clozapine</td>
<td>163</td>
</tr>
<tr>
<td>Clozaril</td>
<td>163</td>
</tr>
<tr>
<td>Cocaine, 27, 35</td>
<td></td>
</tr>
<tr>
<td>addiction medications and</td>
<td>132</td>
</tr>
<tr>
<td>dopamine and</td>
<td>91, 92</td>
</tr>
<tr>
<td>medical consequences of</td>
<td>129</td>
</tr>
<tr>
<td>neurochemicals and</td>
<td>136–137</td>
</tr>
<tr>
<td>social strata and</td>
<td>35</td>
</tr>
<tr>
<td>withdrawal and</td>
<td>93</td>
</tr>
<tr>
<td>See also Stimulants</td>
<td></td>
</tr>
<tr>
<td>Cocaine Anonymous (CA)</td>
<td>21, 80</td>
</tr>
<tr>
<td>Codeine</td>
<td>38</td>
</tr>
<tr>
<td>detoxification and</td>
<td>105</td>
</tr>
<tr>
<td>See also Opioids</td>
<td></td>
</tr>
<tr>
<td>Codependency</td>
<td>75, 185–186</td>
</tr>
<tr>
<td>Codependency Anonymous (CODA),</td>
<td>186</td>
</tr>
<tr>
<td>Cognitive distortions</td>
<td>280–281</td>
</tr>
<tr>
<td>Cognitive therapy</td>
<td>167–168</td>
</tr>
</tbody>
</table>

Cognitive-behavioral therapy (CBT), anxiety disorders and, 177

Collaboration, treatment planning and, 60

College, drinking and drug use in, 73

Coma:
  - depressants and, 33
  - PCP and, 40

Committee to Frame a World Constitution, 227

Community Reinforcement and Family Training (CRAFT), 246–248

Comorbidity of Mental Disorders with Alcohol and Other Drug Abuse, 149


Concealment, non-face-valid questioning and, 52–53

Conduct Disorder, 139, 181

Confessions of an English Opium Eater, 3

Confusion, steroids and, 41

Contemplation, 256–257, 296

Cooney, Ned, 270

Coping skills:
  - RPT and, 278, 285–286
  - teaching, 269–271
  - Cotter, Bruce, 197–198

Counseling skills. See Behavioral change, counseling skills and

Counselors, xviii
  - certified, 23
  - prerequisites, 24–25

Couple therapy, 112

Covey, Stephen, 252, 253

Crack. See Cocaine

Cranberry myth, 41

Crank. See Methamphetamine

Craving, 280, 281, 282

Credibility:
  - assessment and, 47
  - training and, 49

Crime:
  - arrests, 53
  - assessment and, 68

Cronin, Patrick, 80

Crystal meth. See Methamphetamine

Culturally enmeshed addicts, 203–204

Custody, loss of child, 53

Cyclohexyl nitrate, 42

Cyclothymic Disorder, 171

Cylert, 187

Darby’s Carminative, 28

Day hospital programs, xv, 71, 77

Daytop, 16, 83

Deca-Durabolin, 41. See also Anabolic steroids

Dederich, Charles E., 16, 83

Delinquency, assessment and, 68

Delirium:
  - alcohol abstinence syndrome and, 98
  - ketamine and, 41
  - tremens (DTs), 99
  - withdrawal and, 34

Delta-9-tetrahydrocannabinol (THC), 39–40. See also Marijuana

Delusions:
  - alcohol abstinence syndrome and, 98
  - thinking and, 158, 159

Dementia, withdrawal and, 34

Demerol, 38. See also Opioids

Denial, 281, 282
  - dual, 151

Depakote, 171, 172

Dependency, xvii, xviii, 4, 5, 7–8, 10, 17

Dependent Personality Disorder, 185–186

Depressants, 32–33
  - detoxification and, 97
  - medical consequences of, 128–129
  - stages of intoxication, 32
  - synergistic effect, 34
  - tolerance and withdrawal, 33–34

Depression:
  - ketamine and, 41
  - psychoactive substances and, 11
Index 303

Depressive Disorder, Major, 165–167
Avoidant Personality Disorder and, 185
double, 167
DeQuincey, Thomas, 3
Designer drugs, 30
Desipramine, 168
Desoxyn, 187
Desyrel, 168
Detoxification, xv, 75, 93–94
ambulatory, 95–96
goals of, 94
principles of, 94–95
treatment levels, 95–97
treatment protocols, 97–98
agonists and antagonists, 110–112
alcohol, 98–103
methadone, 108–109
nonpharmacological, 112–113
opioids, 105–108, 109–110
outpatient vs. inpatient, 113–114
sedative hypnotics, 103–105
Detoxification from Alcohol and Other Drugs, 94, 98, 102, 103, 108
Dex. See Amphetamine
Dexedrine, 35, 187
Diagnosis:
differential, 157
dual, 75, 150–151
See also Assessment
Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR), xvii, 8, 9,
10, 86, 152
Dialectical behavior therapy (DBT), 183
DiClemente, Carlo C., 254
Dilaudid, 38. See also Opioids
Discipline, spirituality and, 219
Disease model, 14–15, 274
Gorski RPT model and, 294
Disinhibition, depressants and, 32–33
Disorganized behavior, 159, 160, 162
Dissociative anesthetics, 40–41
Disulfiram, 132
Dopamine, 90–92, 137–138
homeostasis and, 93
transporter, 91
Dover’s Powder, 28
Dreaming, intense, 98
Driving while ability impaired (DWAI), 53
Driving while intoxicated (DWI), 6, 53
Dropout, early, 47
Drug Abuse Screening Test (DAST), 51
Drug abuser, xvii, xviii
Drug Enforcement Administration (DEA), 29
Drug-Free Workplace Act of 1988 (DFWA), 205–206
Durabolin, 41. See also Anabolic steroids
Dysthymic disorder, 167
E. See Methyleneoxymethamphetamine (MDMA)
Ecstasy, 29, 35
Federal Analog Act of 1986 and, 30
liquid, 32
medical consequences of, 122
Education:
assessment and, 68
classes, 112
Effexor, 132, 168
Ego, spirituality and, 213–217
Electroconvulsive therapy (ECT), 167, 169, 172
Electrodermal reactivity, 140–141
Electroencephalogram (EEG) measurements, 139
Electrophysiological factors, 140–141
Emotional states, negative, 277
Empathy, 24–25, 252–253
love as, 253–254
Employee assistance program (EAP), 78
Employment, 74
assessment and, 68–69
Enabling, 192
Encounter groups, 83
Encyclopedia Britannica, 227
Endorphins, 90, 137
Enlightenment. See Spirituality

Entheogens, 43

Environment:
  drug-free social, 201–203
  family, xvi, 192–193
  social, 198–199
  work, 12, 204–206

Epinephrine, 138

Erotomanic delusion, 158, 159

Ether, 42. See also Inhalants

Ethyl alcohol. See Alcohol

Euphoria, 36

Event-related potentials (ERPs), 140

Experimental use, 4–6

Extended care, xv, 81–82

Eye movement desensitization and reprocessing (EMDR), 177–178

Faces and Voices of Recovery, 202–203

Face-valid approach, 49–52
  non-face-valid questioning, 52–55

Family history, 67, 135–136, 193–194. See also Environment, family

Family therapy, 75, 112

Fatigue, steroids and, 41

Fearing, James, 245

Federal Analog Act of 1986, 30, 43

Federal Department of Transportation, 74 Federal Register, 206

Fentanyl, 38. See also Opioids

Flashbacks, 39

Flunitrazepam, 32

Fluoxetine, 168

Fluvoxamine. See Luvox

Focus, 150–151

Ford, Betty. See Betty Ford Clinic

Forgetfulness, steroids and, 41

Forget-me pill, 32

The Four Agreements, 221

Freebase. See Cocaine

Funnel-down approach, 156–157

G, 32

Gabapentin, 171–172

Gamma-aminobutyric acid (GABA), functions, 138

Gamma-hydroxybutyrate (GHB), 32

Gases, 42. See also Inhalants

Gastrointestinal disorders, 53

Gay 1890s, 28

Gender, xviii, 17–18, 75

Generalized Anxiety Disorder, 176

Genetic influences, 17, 53, 135–141

Geodon, 163

Glaucoma, 40

Global Assessment of Functioning (GAF), 156

Glomerulosclerosis, 130

Glutamate, 138

Godfrey’s Cordial, 28

Gordon, Judith A., 273

Gorski, Terence T., 294–297

Grand mal seizures, 34, 98, 99

Grandiose type, 158, 159

Gratification, delaying, 220

Group therapy, 112

Gustatory hallucinations, 159, 160

Halcion, 32

Haldol, 163

Halfway house, xv, 71, 82–83

Hallucinations:
  alcohol abstinence syndrome and, 98, 99
  PCP and, 40
  psychotic disorders and, 159–160

Hallucinogens, 39

Halothane, 42. See also Inhalants

Hammer-heading, 29


Hashish, 39–40

Hazelden, 80–81

Heart attacks, steroids and, 41

Hepatitis, xv, 53, 124–126

Herman, Judith, 182

Hero/heroine, 195

Heroin, 27
  agonists and, 110
determining dependence on, 50–51
detoxification and, 105
neurochemicals and, 137
High school, drinking and drug use in, 72–73
Higher power. See Spirituality
High-risk situations, 276–278
Histrionic Personality Disorder, 183–184
Hitting bottom, myth of, xvi, 231
HIV/AIDS, xv, 53, 125, 127–128
Homeostasis, 93
family, 194–195
Homosexuality, 75
Hospitalization treatment, partial, 77–78
Huffing, 12
Humility, spirituality and, 213–217
Hutchins, Robert Maynard, 227
Hyperactivity, 139
Hypodepressive disorder, 167
Hypomanic episodes, 167
Intervention strategies:
early, 57, 72–75
structured, 231–232
history of, 232–235
models
CRAFT, 246–248
executive intervention, 245
Systematic Family Intervention, 244–245
Ten-Hour, 236–244
power of, 248–249
researching, 235–236
Intoxication, biological understanding of, 90–92
Intrapersonal determinants, 277
Intuition. See Spirituality
Irresponsibility, spirituality and, 219
Isocarboxazid, 168
Jealous type, 158, 159
Johnson, Spencer, 221–222
Johnson, Vernon E., 233, 234
Johnson Institute, 233, 234, 244, 246
Joints, 40. See also Marijuana
Jone, Hendrée, 111
Journal of Studies on Alcohol, 73
Kadden, Ronald, 270
Ketamine, 40, 41
LAAM (levo-alpha-acetylmethadol), 112, 131
Lamictal, 171–172
Lamotrigine, 171–172
Lapses, 260
Laughing gas, 42. See also Inhalants
Leshner, Alan I., 127
Letting go, 217–219
Level of care (LOC), xv, 56–58
biomedical conditions and, 119–120
least restrictive, 75, 76
short-term goals, 59, 60
See also specific type
Lexapro, 132
Librium:
anxiety disorders and, 177
substance classifications and, 32
withdrawal and, 105
Lifestyle imbalances, 280, 281
Light therapy, 169
Linehan, Marsha, 183–184
Lithium, 171
Lithobid, 171
Lithonate, 171
Liver disease, xv, 41, 53, 123–124
Liver function test, 100–101
Lost child, 195
Low-dose dependencies, 5
Lung cancer, xv
Luvox:
anxiety disorders and, 177
depressive disorders and, 168
Lysergic acid diethylamide (LSD), 27, 39, 137. See also Psychedelics
M. See Methylenedioxymethamphetamine (MDMA)
Maintenance, 259, 296
Managed care companies (MCOs), 48
Manic episodes, 169, 170
Mapping, behavioral, 247
Marijuana, 27, 39–40
medical consequences of, 128
neurochemicals and, 137
Marijuana Anonymous (MA), 21
Marlatt, Alan, 273
Marplan, 168
Mascot, 195
Masculinization, 41
Mather, Increase, 79
McMunn’s Elixir of Opium, 28
Mecamylamine, 134
Medication management, 75
Medications, 67, 131–134. See specific types
Mellaril, 163
Memory impairment:
alcohol abstinence syndrome and, 98
cannabinoids and, 40
depressants and, 33
PCP and, 40
Mental health history, assessment and, 67
Mental illness, 149–151, 186–188
Mentally ill chemical abuser (MICA), 150–151
Mescaline, 39, 137. See also Psychedelics
Methadone, xv, 38, 77
addiction medications and, 130
agonists and, 110, 111
detoxification and, 105, 108–109
opioid withdrawal and, 108–110
Methamphetamine, 35
medical consequences of, 129
See also Stimulants
Methylenedioxymethamphetamine (MDMA), 30, 35. See also Ecstasy
Methylphenidate, 35. See also Ritalin; Stimulants
Michigan Alcoholism Screening Test (MAST), 50, 51, 55
Microdot. See Lysergic acid diethylamide (LSD)
Miller, William R., 260
Minnesota model, 79–81
Minnesota Multiphasic Personality Inventory (MMPI), 54, 55
Mirtazapine, 168
Mixed episodes, 169, 170
Mixed personality disorder, 186
Moderation management (MM), 200–201
Monoamine oxidase inhibitors (MAOIs), 168, 177
Monti, Peter, 270
Mood Disorders, xv, 139, 152
Mood swings, steroids and, 41
Mood-altering substances. See Psychoactive substances
Moral model, 14–15, 274
Morphine, 28
derivatives, 38
detoxification and, 105
Motivation, 18–20, 40
Motivational Interviewing: Preparing People for Change, 234, 253, 266, 267
Mrs. Winslow’s Soothing Syrup, 28
Multiaxial Evaluation Report Form, 153–156
Multiple sclerosis, inhalants and, 43
Muscle relaxation, depressants and, 33
Naloxone, 110
Naltrexone, 132–133
  addiction medications and, 131
  antagonists and, 110
Nandrolone decanoate, 41. See also Anabolic steroids
Nandrolone phenpropionate, 41. See also Anabolic steroids
Narcissistic Personality Disorder, 184
Narcolepsy, 36
Narcotic Withdrawal Scale, 106–107
Narcotics Anonymous (NA), 21, 80
Nardil, 168
National Cancer Institute (NCI), 36
National Counseling Intervention Services, 245
National Institute on Alcohol Abuse and Alcoholism (NIAA), 271
National Institute on Drug Abuse (NIDA), 23, 31, 36, 90–92
Nefazadone, 168
Negative symptoms, 161
Nembutal, 32
Neuroadaptation, 93
Neurochemicals, 136–139
Neurontin, 171–172
Neurotransmission, 90–92, 138, 139
Nicotine, 36, 53
  addiction medications and, 134
  neurochemicals and, 137
  See also Stimulants
NicVAX, 134
Nitrates, 42–43. See also Inhalants
Nitrous oxide, 42. See also Inhalants
Noble experiment, 79
Nonbizarre delusions, 159
Norepinephrine, 138, 139
Norpramine, 168
North Brothers Island, 84
Nortriptyline, 168
Nucleus acumbens, 137
Obesity, stimulants and, 36
Obsessive Compulsive Disorder (OCD), 11, 175–176, 186
Obsessive-Compulsive Personality Disorder, 176, 186
Odyssey House, 16, 83
Olanzapine, 163, 172
Olfactory hallucinations, 159, 160
One-upmanship, 24
Openness, SUD professionals and, 25
Opiates:
  addiction medications and, 131–132
  detoxification and, 97
Opioid, 38
  detoxification and maintenance therapy, 105–108
  maintenance, xv, 77
  peptides, 138, 139
  substitution therapy, 109
  withdrawal and, 93
Opium, 3, 28
  classification and importance, 30–31
  detoxification and, 105
Organization skills, 25
Outpatient treatment programs, 75–77
  ambivalence and, 19
  detoxification and, 113–114
  early intervention, 74–75
  intensive, xv, 57, 71, 77–78
Overeaters Anonymous, 21
Oxandrin, 41. See also Anabolic steroids
Oxandrolone, 41. See also Anabolic steroids
Oxymetholone, 41. See also Anabolic steroids
P3 Wave deficiencies, 140
Pamelor, 168
Pancreatitis, 53
Panic Disorder, 173–174
Paranoia, marijuana and, 40
Paranoid Personality Disorder, 179–180
Parkinson’s disease, 132
Parnate, 168
Paroxetine. See Paxil
Partial hospitalization, 57
Patient Placement Criteria for the Treatment of Substance-Related Disorders, 55, 57, 60–61, 86, 94, 95, 149
Paxil, 168, 177
Peck, M. Scott, 219, 253
Pemoline. See Cylert
Penal institutions, halfway houses and, 82
People with substance abuse disorders (PSUDs), 15
Percocet, 38, 105. See also Opioids
Persecutory delusion, 158, 159
Personal attribution effect, 279
Personal status, 67
Personality Disorders, xv, 152
Person-in-environment, xvii
Pertofrane, 168
Pharmacotherapy, 168
Phencyclidine (PCP), 40, 41
Phenelzine, 168
Phenobarbital, 32
Phoenix House, 16, 58, 83
Physician’s Desk Reference, xvii
Pink cloud period, 20
Pioneer House, 80
Poppers. See Amyl nitrate
Poppy, history of the, 38
Positive outcome expectancies, 279
Positive symptoms, 161
Posttraumatic Stress Disorder (PTSD), 176
Borderline Personality Disorder and, 182
The Power of Now, 216, 222
The Precious Present, 221–222
Precontemplation, 255–256, 296
Preparation, 257, 296
Prevention, secondary. See Intervention, early
Problematic substance use. See Abuse; Dependence
Prochaska, James O., 254
Prohibition, repeal of, 79–80
Project R.E.T.U.R.N., 16, 83
Prolapse, 292
Prolixin, 163
Propranolol, 132
Prozac, 132
anxiety disorders and, 177
depressive disorders and, 168
Psilocybin, 39. See also Psychedelics
Psychedelics. See Hallucinogens
Psychoactive substances, 4, 5
classifications
general, 31–43
legal, 29–30
history, 27–29
Psychoeducation, 167
Psychologist, xviii
Psychophysiological factors, 139
Psychotherapy, 75
Psychotic Disorders, xv, 152
Psychotic disturbance, withdrawal and, 34
Psychotropic medications, 152
Pulmonary disease, xv
Pure Food and Drug Act of 1906, 28
Quaalude, 105
Quetiapine, 163, 172
Quinlin, Karen Ann, 33, 34
Rapport, 59
Rationalization, 281, 282
Recovery, 191–192, 206–208
culture of addiction and, 203–204
defined, 199–203
eyearly and advanced, 75
family environment and, 192–196
without a, 196–198
four dimensions of, 199
social environment and, 198–199
workplace environment and, 204–206
Recreational drug use, 4, 5–6
Rehabilitation program, 79–81
Rehabitation, 39
Relapse, 18, 259–260
increased risk of, 151–152
See also Relapse prevention therapy (RPT)
Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors, 273
Relapse prevention therapy (RPT), xvii, 75, 271
framework, 273–282
strategies, 282–283
cognitive restructuring, 287–292
coping skills and, 285–287
Gorski model, 294–297
high-risk situations and, 283–285
lifestyle intervention, 292–294
Relationships, assessment and, 67
Reliability, 51
Religious organizations, halfway houses and, 82
Remeron, 168
Residential rehabilitation program, 57–58, 71, 78–84, 96–97
Residual type, 162
Resistance:
dual, 151–152
spirituality and, 217–219
Resources, assessment and, 69
Risperidone, 163
Respiratory problems, xv
cannabinoids and, 40
ketamine and, 41
Responsibilities:
assessment and, 69
spirituality and accepting, 220–221
ReVia, 110, 131, 134
Reward pathway, 91, 92
Ribavirin, 126
Risperidol, 163
Ritalin, 132, 187
The Road Less Traveled, 219, 220, 253
Rohypnol, 32
Roll. See Methyleneoxyamphetamine (MDMA)
Roofies, 32
Ruiz, Don Miguel, 221
Rush, Benjamin, 13
Salvinorin A, 43
Santayana, George, xiv
Scapegoat, 195
Schedule of drugs, 29–30
Schizoid Personality Disorder, 180–181
Avoidant Personality Disorder and, 185
Schizophrenia, 157, 158, 160–161
active or acute phase, 161
residual or stable phase, 161–162
Seasonal affective disorder (SAD), 169
The Seat of the Soul, 214, 218
Seconal:
substance classifications and, 32
withdrawal and, 105
Sedative-hypnotic detoxification:
assessment issues, 103–104
LOC determination, 104–105
pharmacological treatment, 105
See also Depressants
Seemingly irrelevant decisions (SIDs), 281, 282
Seizures, PCP and, 40
Selective serotonin reuptake inhibitors (SSRIs), 168
Self-disclosure, 23–24
Self-efficacy, 276, 284, 287–288
Self-help group, 178
Self-medication, 11, 137, 150
Self-monitoring, 283–284
Sensitivity, increased, 98
Seroquel, 163, 172
Serotonin, 138, 139
Sertraline. See Zoloft
Serum chemistry profile, 100–101
Serum glutamic oxalctic transaminase (SGOT), 124
Serum glutamic pyruvate transaminase (SGPT), 124
INDEX

Serzone, 168
The 7 Habits of Highly Effective People, 252, 253
Severity, SUD, 55–56
Sex drive, steroids and, 41
Sexually transmitted diseases (STDs), 53
Shapiro, Francine, 177–178
Sinusitis, 53
Situational Competency Test (SCT), 286
Situational Confidence Questionnaire (SCQ), 288
Sleeping pills, withdrawal and, 105
Smith, Robert Holbrook, 21, 22, 79–80
Snappers. See Amyl nitrate
Sobriety, xviii
Social phobia, 175, 185
Social pressure, 277
Social support, lack of, 152
Social worker, xviii
Somatic hallucinations, 159, 160
Specific Phobia, 174–175
Specific serotonin reuptake inhibitors (SSRIs), 177
Speech:
PCP, 40
poverty of, 158, 159
Speed. See Methamphetamine
Sperm, steroids and, 41
Spicer, Jerry, 80–81
Spirituality, xvi, 10–13, 14, 209–211, 226, 227
acceptance versus resistance, 217–219
dimensions of life, 212–213
discipline versus irresponsibility, 219–221
ego versus humility, 213–217
explained, 211–212
forgiveness, 226
living in the moment, 221–223
love, 226
Spiritus Contra Spiritum, 14
Splitees, 84
Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES), 260
Step-down programs, 77–78
Stimulants, 34–37
Stress reduction programs, 75
Strokes, steroids and, 41
Student assistance programs (SAPs), 73
Suboxone, 111
Substance Abuse and Mental Health Services Administration (SAMHSA), 55, 109, 112
Substance Abuse Subtle Screening Inventory (SASSI), 51–52, 54–55, 264, 265
3rd Edition (SASSI-3), 55
Substance P, 138
Substance use disorders (SUDs), 3–4
as a biological and spiritual disorder, 10–13
defining, 8–9
disease controversy and, 13–15
professionals, 23–25
progression of, 4–8
providing evidence of, 49–55
treatment (see Treatment)
Substance Use Disorders Diagnostic Schedule (SUDDS), 51
Subutex, 111
Sudden sniffing death (SSD), 43, 122
Suffocation, inhalants and, 43
Suicide, higher risk of, 152
Sunshine. See Lysergic acid diethylamide (LSD)
Support systems, assessment and, 67
Surprise party, 239
Sweats, paroxysmal, 99
Synanon, 16, 83, 84, 219
Synapse, 91
Synergistic effect, 34
Systemic Family Intervention model, 244–245
Tactile sensations, 98, 99
hallucinations, 159, 160
Tegretol, 171
Temperature, elevated, 98
Ten-Hour model, 236–244
Termination, 260
Testicles, steroids and, 41
Testosterone levels, cannabinoids and, 40
Therapeutic communities (TCs), xv, 16, 83–84
Therapist, xviii
Thorazine, 163
Tobacco, 121–122, 128
Tofranil, 168
Tolerance:
  characteristics of, 89
  depressants and, 33–34
  homeostasis and, 93
  stimulants and, 37
Topamax, 172
Topiramate, 134, 172
Trancyclopromine, 168
Tranquilizers:
  substance classifications and, 32
  withdrawal and, 105
Transtheoretical approach, 255
Trauma, psychoactive substances and, 11
Trauma and Recovery, 182
Trazadone, 168
Treatment:
  as a science, 15–16
  effectiveness, 16
  excessive, 77
  goals of, 58–60
  improper, assessment and, 47
  introduction to, 114
  misconceptions, 16–23
  planning, 75 (see also Assessment)
  readiness for, 69
  rising costs, 48
Treatment Improvement Protocol (TIP), 112
Triage Assessment for Addiction Disorders (TAAD), 51, 55
Tricyclic antidepressants (TCAs), 168, 177
Truth, dedication to, 221
Tuberculosis, 129–130
Tuinal, 32, 105
12-Step meetings, 21–23, 76
  difficulty in, 152
  reasons for success, 258–259
  spirituality, 211
Twin studies, 135–136
U.S. Centers for Disease Control and Prevention (CDC), 124–125
U.S. Department of Health and Human Services, 98
U.S. Food and Drug Administration (FDA), 111, 131
Ulcers, 53
Unbundling, 60–61
Undifferentiated type, 162
University of Rhode Island Change Assessment (URICA), 260
Uppers. See Amphetamine
Validity, 51
Valium:
  anxiety disorders and, 177
  medical consequences of, 128
  substance classifications and, 32
  withdrawal and, 105
Valproate, 171
Valproic acid, 171
Venlafaxine, 168
Ventral tegmental area (VTA), 91, 92
Vesicles, 91
Viagra, 29
Vicodin, 105
Videotherapy, 167
Vigabatrin (GVG), 132
Violence, PCP and, 40
Visual hallucinations, 159, 160
Volatile solvents, 42
Weiner, Irving B., 168
Wellbutrin, 135, 168
When They Won’t Quit: A Call to Action for Families, Friends, and Employers of Alcohol and Drug-Addicted People, 197–198

Willmar State Hospital, 80, 85

Wilson, William Griffith, 21, 22, 79–80

Withdrawal:
- characteristics of, 89–90
- depressants and, 33–34
- homeostasis and, 93
- opioids and, 38
- stimulants and, 37

See also Detoxification

Workplace, use of drugs in, 28

World Health Organization, 14, 212

X. See Methyleneoxy methamphetamine (MDMA)

Xanax, 173
- anxiety disorders and, 177
- medical consequences of, 128
- substance classifications and, 32
- withdrawal and, 105

XTC. See Methyleneoxy methamphetamine (MDMA)

Yoga, 75
- hatha, 81

Ziprasidone, 163

Zoloft, 168, 177

Zukav, Gary, 213–214

Zyban, 134, 168

Zyprexa, 163, 172